Roots Analysis has done a detailed study on China Pharmaceutical Contract Manufacturing Services Market, 2020-2030, covering key aspects of the industry and identifying key future growth opportunities.
To order this 200+ page report, which features 85+ figures and 100+ tables, please visit China Pharmaceutical Contract Manufacturing Services Market, 2020-2030
Key Market Insights
- Presently, over 100 CMOs across the globe claim to have manufacturing facilities in China, offering services for pharmaceutical API, intermediates and FDF manufacturing
- CMOs have established manufacturing facilities across different regions of China; Eastern China has emerged as a popular hub, serving as a base of operations for many contract service providers
- The current, installed manufacturing capacity of pharmaceutical CMOs in China is estimated to be over 46 million liters; interestingly, capacity utilization has been observed to be ~75% over the last few years
- Big pharma players have also invested significantly in this region for initiatives related to the establishment or expansion of R&D centers and manufacturing facilities focused on pharmaceutical products
- Innovator companies are expected to continue outsourcing clinical and commercial manufacturing operations to China-based CMOs; the contract services industry in the region is likely to grow at a CAGR of ~8.9%
- In the long-term, the projected future opportunity is anticipated to be well distributed across various market segments, such as different types of products (APIs and FDFs), region (eastern china, southern china, western china) and others
For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html
Table of Contents
- PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
INTRODUCTION
3.1. Chapter Overview
3.2. Need for Outsourcing in the Pharmaceutical Industry
3.3. Overview of the Pharmaceutical Contract Manufacturing
3.4. Evolution of the Pharmaceutical Contract Manufacturing Industry
3.4.1. Traditional Contract Manufacturing Organizations (CMOs)
3.4.2. Modern CMOs
3.5. Services Offered by CMOs
3.6. Pharmaceutical Contract Manufacturing Scenario in China
3.7. Advantages and Challenges associated with Outsourcing Pharmaceutical Manufacturing to China-based CMOs
- CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs / Therapies
4.2.1. Comparison of General Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-related Challenges
- MARKET OVERVIEW
5.1. Chapter Overview
5.2. Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Product (API and FDF)
5.2.5. Analysis by Type of FDF
5.2.6. Analysis by Type of Packaging
5.2.7. Analysis by Manufacturing Facilities
5.3. Non-Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Product (API and FDF)
5.3.5. Analysis by Type of FDF
5.3.6. Analysis by Type of Packaging
5.3.7 Analysis by Manufacturing Facilities
- MANUFACTURING FACILITIES OF PHARMACEUTICAL CMOs IN CHINA
6.1. Chapter Overview
6.2. Chinese Pharmaceutical CMOs: List of Manufacturing Facilities
6.2.1. Analysis by CMO Manufacturing Facilities in Eastern China
6.2.2. Analysis by CMO Manufacturing Facilities in Southern China
6.2.3. Analysis by CMO Manufacturing Facilities in Northern China
- PHARMACEUTICAL MANUFACTURING REGULATIONS IN CHINA
7.1. Chapter Overview
7.1.1. Health Authorities in China
7.1.2. Overview of Regulatory Guidelines in China
- COMPANY PROFILES
8.1. Chapter Overview
8.2. 2Y-Chem
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. China-based Manufacturing Facilities and Capabilities
8.2.4. Recent Developments and Future Outlook
8.3. Aurisco Pharmaceutical
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. China-based Manufacturing Facilities and Capabilities
8.3.4. Recent Developments and Future Outlook
8.4. ChemPartner
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. China-based Manufacturing Facilities and Capabilities
8.4.4. Recent Developments and Future Outlook
8.5. Dorrapharma
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. China-based Manufacturing Facilities and Capabilities
8.5.4. Recent Developments and Future Outlook
8.6. Hubei Biocause Pharmaceutical
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. China-based Manufacturing Facilities and Capabilities
8.6.4. Recent Developments and Future Outlook
8.7. Infoark
8.7.1. Company Overview
8.7.2. Service Portfolio
8.7.3. China-based Manufacturing Facilities and Capabilities
8.7.4. Recent Developments and Future Outlook
8.8. Ningbo Menovo Pharmaceutical
8.8.1. Company Overview
8.8.2. Service Portfolio
8.8.3. China-based Manufacturing Facilities and Capabilities
8.8.4. Recent Developments and Future Outlook
8.9. Shandong Xinhua Pharmaceutical
8.9.1. Company Overview
8.9.2. Service Portfolio
8.9.3. China-based Manufacturing Facilities and Capabilities
8.9.4. Recent Developments and Future Outlook
8.10. Shanghai Acebright Pharmaceuticals
8.10.1. Company Overview
8.10.2. Service Portfolio
8.10.3. China-based Manufacturing Facilities and Capabilities
8.10.4. Recent Developments and Future Outlook
8.11. STA Pharmaceutical
8.11.1. Company Overview
8.11.2. Service Portfolio
8.11.3. China-based Manufacturing Facilities and Capabilities
8.11.4. Recent Developments and Future Outlook
8.12. Zhejiang Huahai Pharmaceutical
8.12.1. Company Overview
8.12.2. Service Portfolio
8.12.3. China-based Manufacturing Facilities and Capabilities
8.12.4. Recent Developments and Future Outlook
- BIG PHARMA INITIATIVES IN CHINA
9.1. Chapter Overview
9.2. Big Pharma Players: List of Initiatives
9.2.1. Analysis by Number of Initiatives
9.2.2. Analysis by Year of Initiative
9.2.3. Analysis by Company and Year of Initiative
9.2.4. Analysis by Type of Initiative
9.3. Benchmark Analysis of Big Pharma Players
9.3.1. Harvey Ball Analysis: Summary of Investments Made
9.3.2. Geographical Analysis by Investments Made (Facility Specific)
- RECENT TRENDS
10.1. Chapter Overview
10.2. CMOs with Manufacturing Facilities in China: List of Partnerships
10.3. Analysis by Year and Type of Partnership
10.4. Logo Landscape of Key Partners
10.5. Geographical Analysis
- CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. CMOs with Manufacturing Facilities in China: Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Location of Chinese Manufacturing Facilities
11.3.2.1. Capacity Analysis: Eastern China
11.3.2.2. Capacity Analysis: Southcentral China
11.3.2.3. Capacity Analysis: Northern China
- SWOT ANALYSIS
12.1. Chapter Overview
12.2. Comparison of SWOT Factors
12.3. Concluding Remarks
- MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030
13.4. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
13.4.1. Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030
13.4.2. Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030
13.4.3. Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030
13.5. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Product
13.5.1. API Contract Manufacturing Services Market in China, 2020-2030
13.5.1.1. API Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
13.5.1.1.1. API Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.1.1.2. API Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.1.1.3. API Contract Manufacturing Services Market in Northern China, 2020-2030
13.5.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030
13.5.2.1. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
13.5.2.1.1. Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.2.1.2. Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.2.1.3. Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030
13.5.2.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Drug Product
13.5.2.2.1. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Solid Drug Product
13.5.2.2.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Liquid and Semi Solid Drug Product
13.5.2.2.3. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Injectable Drug Product
13.5.2.2.4. Drug product Contract Manufacturing Services Market in China, 2020-2030: Share of Other Drug Products
13.6. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Scale of Operation
13.6.1. Clinical Scale Contract Manufacturing Services Market in China, 2020-2030
13.6.2. Commercial Scale Contract Manufacturing Services Market in China, 2020-2030
13.7. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Size of Manufacturers
13.7.1. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies
13.7.2. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-sized Companies
13.7.3. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies
- CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
14.1. Chapter Overview
14.2. Current Opinions and Recuperative Initiatives of Key Players
14.2.1. Wuxi AppTec
14.2.2. Porton Pharma Solutions
14.2.3. Lonza
14.3. Impact on Future Market Opportunity for Pharmaceutical CMOs in China
- CONCLUSION
- APPENDIX 1: TABULATED DATA
- APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
